A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer

Corriveau, Sophie; Pond, Gregory R.; Tang, Grace H; Goffin, John R.

doi:10.1186/s12885-020-07719-y

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Canadian public healthcare dataset, including 105,304 patients diagnosed with lung cancer, reported that spirometry was performed in 90.6% of patients with stage I or II lung cancer, whereas in stage III or IV lung cancer, spirometry was performed in only 54.4%. Of the patients with lung cancer, 34.9% had been previously diagnosed with COPD [ 22 ]. However, considering the low rate of spirometry in patients with advanced lung cancer, the actual prevalence of COPD in this patient population is expected to be higher.…”

Section: Pulmonary Outcomesmentioning

confidence: 99%

Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review

2022

Tuberc Respir Dis

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammation characterized by fixed airflow limitation and chronic respiratory symptoms, such as cough, sputum, and dyspnea. COPD is a progressive disease characterized by a decline in lung function. During the natural course of the disease, acute deterioration of symptoms leading to hospital visits can occur and influence further disease progression and subsequent exacerbation. Moreover, COPD is not only restricted to pulmonary manifestations but can present with other systemic diseases as comorbidities or systemic manifestations, including lung cancer, cardiovascular disease, pulmonary hypertension, sarcopenia, and metabolic abnormalities. These pulmonary and extrapulmonary conditions lead to the aggravation of dyspnea, physical inactivity, decreased exercise capacity, functional decline, reduced quality of life, and increased mortality. In addition, pneumonia, which is attributed to both COPD itself and an adverse effect of treatment (especially the use of inhaled and/or systemic steroids), can occur and lead to further deterioration in the prognosis of COPD. This review summarizes the long-term outcomes of patients with COPD. In addition, recent studies on the prediction of adverse outcomes are summarized in the last part of the review.

show abstract

Section: Pulmonary Outcomesmentioning

confidence: 99%

Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review

2022

Tuberc Respir Dis

View full text Add to dashboard Cite

show abstract

“…Chronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation and fixed airflow obstruction [117]. Over a third of the individuals with lung cancer have a prior diagnosis of COPD [118]. Interstitial pneumonia, a condition that causes progressive fibrosis, is a known risk factor for lung carcinogenesis independent of smoking; epidemiologically, the risk of lung carcinogenesis is 6.42 times in healthy subjects [5].…”

Section: Chronic Inflammationmentioning

confidence: 99%

Relationship between Lung Carcinogenesis and Chronic Inflammation in Rodents

Nakano‐Narusawa

Yokohira

Yamakawa

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related deaths, with an estimated 1.76 million deaths reported in 2018. Numerous studies have focused on the prevention and treatment of lung cancer using rodent models. Various chemicals, including tobacco-derived agents induce lung cancer and pre-cancerous lesions in rodents. In recent years, transgenic engineered rodents, in particular, those generated with a focus on the well-known gene mutations in human lung cancer (KRAS, EGFR, and p53 mutations) have been widely studied. Animal studies have revealed that chronic inflammation significantly enhances lung carcinogenesis, and inhibition of inflammation suppresses cancer progression. Moreover, the reduction in tumor size by suppression of inflammation in animal experiments suggests that chronic inflammation influences the promotion of tumorigenesis. Here, we review rodent lung tumor models induced by various chemical carcinogens, including tobacco-related carcinogens, and transgenics, and discuss the roles of chronic inflammation in lung carcinogenesis.

show abstract

“…COPD is associated with an increased lung cancer development, which is often underestimated in clinical practice. Studies have reported that 40-70% of lung cancer cases are complicated with COPD ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial

Dong,

Yin,

Liu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe first-line standard treatment option for patients with NSCLC complicated with Chronic obstructive pulmonary disease (COPD) is still unclear and relies on the treatment option of NSCLC alone. To date, a limited number of retrospective studies have explored the efficacy and safety of immunotherapy in patients with NSCLC complicated with COPD. We therefore designed this study to further explore the efficacy and safety of first-line immunotherapy in patients with NSCLC complicated with COPD.MethodsThis study was designed as a single-armed, single-center, prospective, phase II clinical study. It will include 30 advanced (stage IV) NSCLC combined with COPD primary treatment subjects. Each subject’s diagnosis will be confirmed by clinical, radiographic, pathologic, and pulmonary function evaluation. A fixed dose of 200 mg pembrolizumab will be administered by intravenous infusion on day1 every 3 weeks (Q3W). The management of stable and acute exacerbations of COPD include home oxygen therapy, and the use of conventional medications are also administered. Imaging evaluation will be performed every 6 weeks for 6 months from the first pembrolizumab dose and approximately every 12 weeks thereafter until disease progression or early withdrawal. COPD status will be evaluated every 3 months by pulmonary function, GOLD grading, mMRC score, CAT score, ABCD grouping, and AECOPD severity. The primary outcome is Progression-free survival. The secondary outcome measures include objective response rate, overall survival, rate of acute exacerbations of COPD (times/year), lung function, mMRC score, CAT score, impact of treatment on patient’s health-related quality of life, antibiotic use (including duration and classes), and adverse events associated with immune checkpoint inhibitors. Exploratory endpoint is to explore the association between COPD grade and the degree of immune cell (CD4+ T lymphocytes and CD8+ T lymphocytes) infiltration, as well as the association between COPD grade and the efficacy of immune checkpoint inhibitors.Clinical trial registrationClinicalTrials.gov, identifier NCT05578222.

show abstract

A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer

Cited by 3 publications

References 22 publications

Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review

Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review

Relationship between Lung Carcinogenesis and Chronic Inflammation in Rodents

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial

Contact Info

Product

Resources

About